Early post-transplant hyperglycemia and post-transplant diabetes mellitus following heart transplantation

References

• Newman JD, Schlendorf KH, Cox ZL, et al. Post-transplant diabetes mellitus following heart transplantation. J Heart Lung Transplant. 2022;41(11):1537–46. doi: 10.1016/j.healun.2022.07.011
   PubMed Web of Science ®Google Scholar
• Vest AR, Cherikh WS, Noreen SM, et al. New-onset diabetes mellitus after adult heart transplantation and the risk of renal dysfunction or mortality. Transplantation. 2022;106(1):178–187. doi: 10.1097/TP.0000000000003647
   PubMed Web of Science ®Google Scholar
• Kim HJ, Jung SH, Kim JJ, et al. New-onset diabetes mellitus after heart transplantation – incidence, risk factors and impact on clinical outcome. Circulation. 2017;81(6):806–814. doi: 10.1253/circj.CJ-16-0963
   Web of Science ®Google Scholar
• Zhang M, Han Y, Yuan Y, et al. Risk factors for new-onset diabetes mellitus after heart transplantation in Chinese patients: a single center experience. Ann Nutr Metab. 2019;74(4):331–8. doi: 10.1159/000500138
   PubMed Web of Science ®Google Scholar
• Sharif A, Hecking M, De Vries AP, et al. Proceedings from an international consensus meeting on posttransplantation diabetes mellitus: recommendations and future directions. Am J Transplant. 2014;14(9):1992–2000. doi: 10.1111/ajt.12850
   PubMed Web of Science ®Google Scholar
• Lund LH, Edwards LB, Dipchand AI, et al. The registry of the international society for heart and lung transplantation: thirty-third adult heart transplantation report—2016; focus theme: primary diagnostic indications for transplant. J Heart Lung Transplant. 2016;35(10):1158–1169. doi: 10.1016/j.healun.2016.08.017
   PubMedGoogle Scholar
• Shah KS, Kittleson MM, Kobashigawa JA. Updates on heart transplantation. Curr Heart Fail Rep. 2019;16(5):150–156. doi: 10.1007/s11897-019-00432-3
   PubMedGoogle Scholar
• ANZOD Registry. Section 12: deceased organ transplant outcome data. 2019 annual report. Adelaide (SA): Australia and New Zealand Dialysis and Transplant Registry; 2019.
   Google Scholar
• ANZOD Registry. Section 7: deceased donor heart donation. 2022 annual report. Adelaide (SA): Australia and New Zealand Dialysis and Transplant Registry; 2022.
   Google Scholar
• Munshi VN, Saghafian S, Cook CB, et al. Incidence, risk factors, and trends for postheart transplantation diabetes mellitus. Am J Cardiol. 2020;125(3):436–40. doi: 10.1016/j.amjcard.2019.10.054
   PubMed Web of Science ®Google Scholar
• Cehic MG, Nundall N, Greenfield JR, et al. Management strategies for posttransplant diabetes mellitus after heart transplantation: A review. J Transplant. 2018;2018:1–14. doi: 10.1155/2018/1025893
   Google Scholar
• Zielińska K, Kukulski L, Wróbel M, et al. Prevalence and risk factors of new-onset diabetes after transplantation (NODAT). Ann Transplant. 2020;25:e926556. doi: 10.12659/AOT.926556
   PubMed Web of Science ®Google Scholar
• Chowdhury TA, Wahba M, Mallik R, et al. Association of British clinical diabetologists and renal association guidelines on the detection and management of diabetes post solid organ transplantation. Diabetic Med. 2021;38(6):e14523. doi: 10.1111/dme.14523
   PubMed Web of Science ®Google Scholar
• Iqbal A, Zhou K, Kashyap SR, et al. Early post-renal transplant hyperglycemia. J Clin Endocrinol Metab. 2021;107(2):549–562. doi: 10.1210/clinem/dgab697
   Web of Science ®Google Scholar
• Eide IA, Halden TAS, Hartmann A, et al. Limitations of hemoglobin A1c for the diagnosis of posttransplant diabetes mellitus. Transplantation. 2015;99(3):629–35. doi: 10.1097/TP.0000000000000376
   PubMed Web of Science ®Google Scholar
• Chakkera HA, Weil EJ, Castro J, et al. Hyperglycemia during the immediate period after kidney transplantation. Clin J Am Soc Nephrol. 2009;4(4):853–9. doi: 10.2215/CJN.05471008
   PubMed Web of Science ®Google Scholar
• Gupta S, Bansal S, Böckerman P. Does a rise in BMI cause an increased risk of diabetes?: evidence from India. PloS One. 2020;15(4):e0229716. doi: 10.1371/journal.pone.0229716
   PubMed Web of Science ®Google Scholar
• Park SC, Yoon YD, Jung HY, et al. Effect of transient post-transplantation hyperglycemia on the development of diabetes mellitus and transplantation outcomes in kidney transplant recipients. Transplant Proc. 2015;47(3):666–671. doi: 10.1016/j.transproceed.2014.11.053
   PubMed Web of Science ®Google Scholar
• Ling Q, Xu X, Xie H, et al. New-onset diabetes after liver transplantation: a national report from China liver transplant registry. Liver Int. 2016;36(5):705–12. doi: 10.1111/liv.13042
   PubMed Web of Science ®Google Scholar
• Kgosidialwa O, Blake K, O’Connell O, et al. Post-transplant diabetes mellitus associated with heart and lung transplant. Ir J Med Sci. 2020;189(1):185–189. doi: 10.1007/s11845-019-02068-7
   PubMed Web of Science ®Google Scholar
• Zhao T, Zhao Y, Zong A, et al. Association of body mass index and fasting plasma glucose concentration with post-transplantation diabetes mellitus in Chinese heart transplant recipients. J Int Med Res. 2020;48(3):1–13. doi: 10.1177/0300060520910629
   Web of Science ®Google Scholar
• Porrini EL, Díaz JM, Moreso F, et al. Clinical evolution of post-transplant diabetes mellitus. Nephrol Dialysis Transplantation. 2016;31(3):495–505. doi: 10.1093/ndt/gfv368
   PubMed Web of Science ®Google Scholar
• Feng KY, Henricksen EJ, Wayda B, et al. Impact of diabetes mellitus on clinical outcomes after heart transplantation. Clin Transplant. 2021;35(11):e14460. doi: 10.1111/ctr.14460
   PubMed Web of Science ®Google Scholar
• Raven LM, Muir CA, Macdonald PS, et al. Diabetes medication following heart transplantation: a focus on novel cardioprotective therapies—A joint review from endocrinologists and cardiologists. Acta Diabetol. 2022;60(4):471–80. doi: 10.1007/s00592-022-02018-3
   PubMed Web of Science ®Google Scholar
• Aouad LJ, Clayton P, Wyburn KR, et al. Evolution of glycemic control and variability after kidney transplant. Transplantation. 2018;102(9):1563–8. doi: 10.1097/TP.0000000000002155
   PubMed Web of Science ®Google Scholar
• Wang R, Zhang Y, Fan J, et al. Risk factors for new-onset diabetes mellitus after heart transplantation: a nomogram approach. Transplant Proc. 2022;54(3):762–768. doi: 10.1016/j.transproceed.2022.01.030
   PubMed Web of Science ®Google Scholar
• Sparks JD, Cantor RS, Pruitt E, et al. New‐onset diabetes after pediatric heart transplantation: a review of the pediatric heart transplant study. Pediatr Transplant. 2019;23(5):e13476. doi: 10.1111/petr.13476
   PubMed Web of Science ®Google Scholar
• Sehgal S, Bock MJ, Louks Palac H, et al. New-onset diabetes mellitus after heart transplantation in children – incidence and risk factors. Pediatr Transplant. 2016;20(7):963–969. doi: 10.1111/petr.12759
   PubMed Web of Science ®Google Scholar
• Xie L, Tang W, Wang X, et al. Pretransplantation risk factors associated with new-onset diabetes after living-donor kidney transplantation. Transplant Proc. 2016;48(10):3299–3302. doi: 10.1016/j.transproceed.2016.10.026
   PubMed Web of Science ®Google Scholar
• Shaked A, Loza B-L, Van Loon E, et al. Donor and recipient polygenic risk scores influence the risk of post-transplant diabetes. Nature Med. 2022;28(5):999–1005. doi: 10.1038/s41591-022-01758-7
   PubMed Web of Science ®Google Scholar
• McCaughan JA, McKnight AJ, Maxwell AP. Genetics of new-onset diabetes after transplantation. J Am Soc Nephrol. 2014;25(5):1037–49. doi: 10.1681/ASN.2013040383
   PubMed Web of Science ®Google Scholar
• Hsu WC, Araneta MRG, Kanaya AM, et al. BMI cut points to identify at-risk Asian Americans for type 2 diabetes screening. Diabetes Care. 2015;38(1):150–8. doi: 10.2337/dc14-2391
   PubMed Web of Science ®Google Scholar
• Ferrannini E, Natali A, Bell P, et al. Insulin resistance and hypersecretion in obesity. European group for the study of insulin resistance (EGIR). J Clin Investig. 1997;100(5):1166–73. doi: 10.1172/JCI119628
   PubMed Web of Science ®Google Scholar
• Lee MJ, Park JT, Park KS, et al. Normal body mass index with central obesity has increased risk of coronary artery calcification in Korean patients with chronic kidney disease. Kidney Int. 2016;90(6):1368–76. doi: 10.1016/j.kint.2016.09.011
   PubMed Web of Science ®Google Scholar
• Cao Q, Yu S, Xiong W, et al. Waist-hip ratio as a predictor of myocardial infarction risk: a systematic review and meta-analysis. Medicine. 2018;97(30):e11639. doi: 10.1097/MD.0000000000011639
   PubMed Web of Science ®Google Scholar
• Gwon JG, Choi J, Jung CW, et al. Impact of changes in waist-to-hip ratio after kidney transplantation on cardiovascular outcomes. Sci Rep. 2021;11(1):783. doi: 10.1038/s41598-020-80266-5
   PubMed Web of Science ®Google Scholar
• Pinar U, Rod X, Mageau A, et al. Surgical complications risk in obese and overweight recipients for kidney transplantation: a predictive morphometric model based on sarcopenia and vessel-to-skin distance. World J Urol. 2021;39(6):2223–2230. doi: 10.1007/s00345-020-03407-5
   PubMed Web of Science ®Google Scholar
• Oniscu GC, Abramowicz D, Bolignano D, et al. Management of obesity in kidney transplant candidates and recipients: a clinical practice guideline by the DESCARTES working group of ERA. Nephrol Dialysis Transplantation. 2021;37(Supplement_1):1–15. doi: 10.1093/ndt/gfab310
   PubMedGoogle Scholar
• Tamez-Pérez HE. Steroid hyperglycemia: prevalence, early detection and therapeutic recommendations: a narrative review. World J Diabetes. 2015;6(8):1073. doi: 10.4239/wjd.v6.i8.1073
   PubMedGoogle Scholar
• BioRender. Created with BioRender.com. Toronto (ON): BioRender; 2023.
   Google Scholar
• Hecking M, Sharif A, Eller K, et al. Management of post‐transplant diabetes: immunosuppression, early prevention, and novel antidiabetics. Transplant Int. 2021;34(1):27–48. doi: 10.1111/tri.13783
   PubMed Web of Science ®Google Scholar
• Haller MC, Royuela A, Nagler EV, et al. Steroid avoidance or withdrawal for kidney transplant recipients. Cochrane Database Syst Rev. 2016;2016(8):CD005632. doi: 10.1002/14651858.CD005632.pub3
   PubMedGoogle Scholar
• Thomusch O, Wiesener M, Opgenoorth M, et al. Rabbit-ATG or basiliximab induction for rapid steroid withdrawal after renal transplantation (harmony): an open-label, multicentre, randomised controlled trial. Lancet. 2016;388(10063):3006–16. doi: 10.1016/S0140-6736(16)32187-0
   PubMed Web of Science ®Google Scholar
• Midtvedt K, Hjelmesaeth J, Hartmann A, et al. Insulin resistance after renal transplantation: the effect of steroid dose reduction and withdrawal. J Am Soc Nephrol. 2004;15(12):3233–9. doi: 10.1097/01.ASN.0000145435.80005.1E
   PubMed Web of Science ®Google Scholar
• Dai C, Walker JT, Shostak A, et al. Tacrolimus- and sirolimus-induced human β cell dysfunction is reversible and preventable. JCI Insight. 2020;5(1):e130770. doi: 10.1172/jci.insight.130770
   PubMed Web of Science ®Google Scholar
• Triñanes J, Rodriguez-Rodriguez AE, Brito-Casillas Y, et al. Deciphering tacrolimus-induced toxicity in pancreatic β cells. Am J Transplant. 2017;17(11):2829–40. doi: 10.1111/ajt.14323
   PubMed Web of Science ®Google Scholar
• Torres A, Hernández D, Moreso F, et al. Randomized controlled trial assessing the impact of tacrolimus versus cyclosporine on the incidence of posttransplant diabetes mellitus. Kidney Int Rep. 2018;3(6):1304–15. doi: 10.1016/j.ekir.2018.07.009
   PubMed Web of Science ®Google Scholar
• Saxton RA, Sabatini DM. mTOR signaling in growth, metabolism, and disease. Cell. 2017;168(6):960–976. doi: 10.1016/j.cell.2017.02.004
   PubMed Web of Science ®Google Scholar
• Blandino-Rosano M, Barbaresso R, Jimenez-Palomares M, et al. Loss of mTORC1 signalling impairs β-cell homeostasis and insulin processing. Nat Commun. 2017;8(1):16014. doi: 10.1038/ncomms16014
   PubMedGoogle Scholar
• Raven LM, Muir CA, Pouliopoulos J, et al. Metabolic sequelae of everolimus treatment after cardiac transplant: a hypothesis-generating study. Heart Lung & Circulation. 2023;32(9):1076–1079. doi: 10.1016/j.hlc.2023.05.014
   PubMed Web of Science ®Google Scholar
• Shivaswamy V, Boerner B, Larsen J. Post-transplant diabetes mellitus: causes, treatment, and impact on outcomes. Endocrine Reviews. 2016;37(1):37–61. doi: 10.1210/er.2015-1084
   PubMed Web of Science ®Google Scholar
• Schweer T, Gwinner W, Scheffner I, et al. High impact of rejection therapy on the incidence of post-transplant diabetes mellitus after kidney transplantation. Clin Transplant. 2014;28(4):512–9. doi: 10.1111/ctr.12329
   PubMed Web of Science ®Google Scholar
• Einollahi B, Motalebi M, Salesi M, et al. The impact of cytomegalovirus infection on new-onset diabetes mellitus after kidney transplantation: a review on current findings. J Nephropathol. 2014;3(4):139–148. doi: 10.12860/jnp.2014.27
   PubMedGoogle Scholar
• Montefusco L, Ben Nasr M, D’Addio F, et al. Acute and long-term disruption of glycometabolic control after SARS-CoV-2 infection. Nat Metab. 2021;3(6):774–85. doi: 10.1038/s42255-021-00407-6
   PubMedGoogle Scholar
• Xie Y, Xu E, Bowe B, et al. Long-term cardiovascular outcomes of COVID-19. Nature Med. 2022;28(3):583–90. doi: 10.1038/s41591-022-01689-3
   PubMed Web of Science ®Google Scholar
• Rizvi AA, Kathuria A, Al Mahmeed W, et al. Post-COVID syndrome, inflammation, and diabetes. J Diabetes Complications. 2022;36(11):108336. doi: 10.1016/j.jdiacomp.2022.108336
   PubMed Web of Science ®Google Scholar
• Peled Y, Ram E, Lavee J, et al. Hypomagnesemia is associated with new-onset diabetes mellitus following heart transplantation. Cardiovasc Diabetol. 2019;18(1):132. doi: 10.1186/s12933-019-0939-5
   PubMed Web of Science ®Google Scholar
• Han T, Lan L, Qu R, et al. Temporal relationship between hyperuricemia and insulin resistance and its impact on future risk of hypertension. Hypertension. 2017;70(4):703–11. doi: 10.1161/HYPERTENSIONAHA.117.09508
   PubMed Web of Science ®Google Scholar
• Chakkera HA, Knowler WC, Devarapalli Y, et al. Relationship between inpatient hyperglycemia and insulin treatment after kidney transplantation and future new onset diabetes mellitus. Clin J Am Soc Nephrol. 2010;5(9):1669–75. doi: 10.2215/CJN.09481209
   PubMed Web of Science ®Google Scholar
• Nagaraja P, Ravindran V, Morris-Stiff G, et al. Role of insulin resistance indices in predicting new-onset diabetes after kidney transplantation. Transplant Int. 2013;26(3):273–80. doi: 10.1111/tri.12026
   PubMed Web of Science ®Google Scholar
• Leon BM, Maddox TM. Diabetes and cardiovascular disease: epidemiology, biological mechanisms, treatment recommendations and future research. World J Diabetes. 2015;6(13):1246–1258. doi: 10.4239/wjd.v6.i13.1246
   PubMed Web of Science ®Google Scholar
• Ram E, Lavee J, Tenenbaum A, et al. Metformin therapy in patients with diabetes mellitus is associated with a reduced risk of vasculopathy and cardiovascular mortality after heart transplantation. Cardiovasc Diabetol. 2019;18(1):118. doi: 10.1186/s12933-019-0925-y
   PubMed Web of Science ®Google Scholar
• Hahr AJ, Molitch ME. Management of diabetes mellitus in patients with chronic kidney disease. Clin Diabetes Endocrinol. 2015;1(1):2. doi: 10.1186/s40842-015-0001-9
   PubMedGoogle Scholar
• Wallia A, Schmidt K, Oakes DJ, et al. Glycemic control reduces infections in post-liver transplant patients: results of a prospective, randomized study. J Clin Endocrinol Metab. 2017;102(2):451–459. doi: 10.1210/jc.2016-3279
   PubMed Web of Science ®Google Scholar
• Londero TM, Giaretta LS, Farenzena LP, et al. Microvascular complications of posttransplant diabetes mellitus in kidney transplant recipients: a longitudinal study. J Clin Endocrinol Metab. 2019;104(2):557–67. doi: 10.1210/jc.2018-01521
   PubMed Web of Science ®Google Scholar
• Burroughs TE, Swindle J, Takemoto S, et al. Diabetic complications associated with new-onset diabetes mellitus in renal transplant recipients. Transplantation. 2007;83(8):1027–34. doi: 10.1097/01.tp.0000259617.21741.95
   PubMed Web of Science ®Google Scholar
• Zinman B, Lachin JM, Empagliflozin IS. Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med. 2016;374(11):1094.
   PubMed Web of Science ®Google Scholar
• Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375(19):1834–44. doi: 10.1056/NEJMoa1607141
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. Introduction: standards of medical care in diabetes—2022. Diabetes Care. 2021;45(Supplement_1):S1–2. doi: 10.2337/dc22-Sint
   Google Scholar
• Gosmanov AR, Dagogo-Jack S. Predicting, managing and preventing new-onset diabetes after transplantation. Minerva Endocrinol. 2012;37(3):233–246.
   PubMedGoogle Scholar
• Hecking M, Haidinger M, Döller D, et al. Early basal insulin therapy decreases new-onset diabetes after renal transplantation. J Am Soc Nephrol. 2012;23(4):739–49. doi: 10.1681/ASN.2011080835
   PubMed Web of Science ®Google Scholar
• Schwaiger E, Krenn S, Kurnikowski A, et al. Early postoperative basal insulin therapy versus standard of care for the prevention of diabetes mellitus after kidney transplantation: a multicenter randomized trial. J Am Soc Nephrol. 2021;32(8):2083–98. doi: 10.1681/ASN.2021010127
   PubMed Web of Science ®Google Scholar
• Lo C, Toyama T, Oshima M, et al. Glucose-lowering agents for treating pre-existing and new-onset diabetes in kidney transplant recipients. Cochrane Database Syst Rev. 2020;2020(8): CD009966. doi: 10.1002/14651858.CD009966.pub3
   Google Scholar
• Kuningas K, Driscoll J, Mair R, et al. Comparing glycaemic benefits of active versus passive lifestyle intervention in kidney allograft recipients: a randomized controlled trial. Transplantation. 2020;104(7):1491–99. doi: 10.1097/TP.0000000000002969
   PubMed Web of Science ®Google Scholar
• Squires RW, Bonikowske AR. Cardiac rehabilitation for heart transplant patients: considerations for exercise training. Prog Cardiovasc Dis. 2022;70:40–8. doi: 10.1016/j.pcad.2021.12.003
   PubMed Web of Science ®Google Scholar
• Costa R, Moreira E, Silva Cardoso J, et al. Effectiveness of exercise-based cardiac rehabilitation for heart transplant recipients: a systematic review and meta-analysis. Health Serv Insights. 2023;16:11786329231161482. doi: 10.1177/11786329231161482
   Web of Science ®Google Scholar
• Li J, Chong A, Carey S. Dietary interventions on the prevention and management of diabetes in post‐kidney transplantation – a systematic review. Nephrology. 2022;27(3):269–80. doi: 10.1111/nep.13982
   PubMed Web of Science ®Google Scholar
• Peled Y, Lavee J, Raichlin E, et al. Metformin therapy reduces the risk of malignancy after heart transplantation. J Heart Lung Transplant. 2017;36(12):1350–57. doi: 10.1016/j.healun.2017.06.009
   PubMed Web of Science ®Google Scholar
• Lipska KJ, Bailey CJ, Inzucchi SE. Use of metformin in the setting of mild-to-moderate renal insufficiency. Diabetes Care. 2011;34(6):1431–7. doi: 10.2337/dc10-2361
   PubMed Web of Science ®Google Scholar
• Muir CA, Greenfield JR, MacDonald PS. Empagliflozin in the management of diabetes mellitus after cardiac transplantation. J Heart Lung Transplant. 2017;36(8):914–6. doi: 10.1016/j.healun.2017.05.005
   PubMed Web of Science ®Google Scholar
• Cehic MG, Muir CA, Greenfield JR, et al. Efficacy and safety of Empagliflozin in the management of diabetes mellitus in heart transplant recipients. Transplant Direct. 2019;5(5):e450. doi: 10.1097/TXD.0000000000000885
   PubMed Web of Science ®Google Scholar
• Sammour Y, Nassif M, Magwire M, et al. Effects of GLP-1 receptor agonists and SGLT-2 inhibitors in heart transplant patients with type 2 diabetes: initial report from a cardiometabolic center of excellence. J Heart Lung Transplant. 2021;40(6):426–9. doi: 10.1016/j.healun.2021.02.012
   PubMed Web of Science ®Google Scholar
• Halden TAS, Kvitne KE, Midtvedt K, et al. Efficacy and safety of Empagliflozin in renal transplant recipients with posttransplant diabetes mellitus. Diabetes Care. 2019;42(6):1067–74. doi: 10.2337/dc19-0093
   PubMed Web of Science ®Google Scholar
• Zelniker TA, Braunwald E. Mechanisms of cardiorenal effects of sodium-glucose cotransporter 2 inhibitors: JACC state-of-the-art review. J Am Coll Cardiol. 2020;75(4):422–34. doi: 10.1016/j.jacc.2019.11.031
   PubMed Web of Science ®Google Scholar
• Azoulay L, Suissa S. Sulfonylureas and the risks of cardiovascular events and death: a methodological meta-regression analysis of the observational studies. Diabetes Care. 2017;40(5):706–14. doi: 10.2337/dc16-1943
   PubMed Web of Science ®Google Scholar
• Dalem J, Brouwers MCGJ, Stehouwer CDA, et al. Risk of hypoglycaemia in users of sulphonylureas compared with metformin in relation to renal function and sulphonylurea metabolite group: population based cohort study. BMJ. 2016;354:i3625. doi: 10.1136/bmj.i3625
   PubMedGoogle Scholar
• Attallah N, Yassine L. Linagliptin in the management of type 2 diabetes mellitus after kidney transplant. Transplant Proc. 2021;53(7):2234–2237. doi: 10.1016/j.transproceed.2021.07.035
   PubMed Web of Science ®Google Scholar
• Haidinger M, Werzowa J, Hecking M, et al. Efficacy and safety of vildagliptin in new-onset diabetes after kidney transplantation—A randomized, double-blind, placebo-controlled trial. Am J Transplant. 2014;14(1):115–23. doi: 10.1111/ajt.12518
   PubMed Web of Science ®Google Scholar
• Raven LM, Muir CA, Kessler Iglesias C, et al. Sodium glucose co-transporter 2 inhibition with empagliflozin on metabolic, cardiac and renal outcomes in recent cardiac transplant recipients (EMPA-HTx): protocol for a randomised controlled trial. BMJ Open. 2023;13(3):e069641. doi: 10.1136/bmjopen-2022-069641
   PubMed Web of Science ®Google Scholar